Citations

Clear

1827 citation(s) found for "Su, Emily".

Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma
Ijad, Nazanin, Yamazawa, Erika , Burgenske, Danielle, Torrini, Consuelo , Carlson, Brett L. , Summers, Elizabeth J, Migliarese, Christian, Marion, Braxton, Zhang, Britney Shela, Sullivan, Emily, Ellington, Claudia, Sasisekharan, Varun, Decker, Paul A, Kosel, Matthew, Eckel‐Passow, Jeanette E. , Galanis, E., Brastianos, Priscilla K, Brastianos, Priscilla K. , Waller, Katie L. , Nayyar, Naema , Burgenske, Danielle M. , Summers, Elizabeth, Marion, Braxton, Decker, Paul A. , Kosel, Matthew , Sarkaria, Jann N. , Wakimoto, Hiroaki , Vaubel, Rachael A. , Brastianos, Priscilla K. , Torrini, Consuelo , Eckel-Passow, Jeanette E , Galanis, Evanthia , Vaubel, Rachael A

Mayo Clinic

Neuro-Oncology Advances | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/noajnl/vdag210 | PMID 42825158 Get It

Abstract Background Meningiomas lack effective therapies for recurrent or aggressive disease. NF2 inactivation, commonly in meningioma, may sensitize tumors to FAK inhibition and interact with MAPK signaling. This study investigated the therapeutic activity of defactinib (FAK inhibitor) and avutometinib (RAF/MEK inhibitor) alone and in combination in preclinical meningioma models. Methods MAPK-altered meningioma cell lines, IOMM-Lee (NF2 wild-type, BRAF p.V600E) and CH157-MN (NF2 mutant, NRAS p.Q61K), BenMen-1 (NF2 mutant, MAPK wild-type), and three patient-derived NF2 mutant cell lines were cultured in matrigel and treated with defactinib and avutometinib in 3D cell viability assays. In vivo, flank and intracranial xenograft models of IOMM-Lee and CH157-MN were treated with VS-4718 (FAK inhibitor, superior pharmokinetics in mice), avutometinib, or combination. Tumor growth, survival, and pharmacokinetic/pharmacodynamic properties were assessed. Results In vitro, combination therapy showed synergistic or additive effects in CH157-MN and IOMM-Lee cells, respectively. Defactinib alone demonstrated activity in NF2-mutant patient-derived and BenMen-1 cells, while avutometinib did not. In vivo, avutometinib monotherapy suppressed tumor growth and extended survival in both flank and intracranial xenograft models, with evidence of favorable pharmacokinetic properties and target pathway inhibition in intracranial tumors. Combination therapy provided enhanced and sustained control of flank CH157-MN meningioma compared to avutometinib alone but did not significantly improve survival over avutometinib alone in intracranial models. Conclusions Avutometinib demonstrated robust anti-tumor effects in flank and intracranial models of MAPK-altered meningioma. Combination benefits were context dependent. Defactinib activity in NF2-mutant patient-derived cells without targetable MAPK-kinase alterations highlights the importance of genomic biomarkers to guide personalized strategies.
Incidence of Acute Cystoid Macular Edema After Penetrating Keratoplasty and Endothelial Keratoplasty
Qozat, Ibrahim , Abubaker, Yazan , Vasu, Pranav, Wagner, Isabella, Lentz, Conner, Ahuja, Abhimanyu, Miller, Darby, Stewart, Michael, Dorairaj, Syril, Qozat, Ibrahim , Vasu, Pranav , Wagner, Isabella V. , Dorairaj, Emily , Miller, Darby D. , Stewart, Michael W., Dorairaj, Syril

Mayo Clinic

Klinische Monatsblätter für Augenheilkunde | August 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2932-7648 | PMID 42570678 Get It

Abstract Introduction Cystoid macular edema (CME) is a recognized complication associated with penetrating keratoplasty (PK) and Endothelial Keratoplasty (EK). The purpose of this study was to determine the incidence of acute CME within the first 6 months after PK, Descemet stripping automated EK, or Descemet’s membrane EK. Methods A retrospective cohort analysis of the TriNetX United States collaborative database was conducted. Patients with a diagnosis of Fuchs dystrophy or keratoconus who underwent PK or EK between January 1, 2004 and August 30, 2024 were included. Those with a history of uveitis, retinal vascular occlusion, diabetic macular edema, or prior vitrectomy were excluded. Outcomes and diagnoses were defined using current procedural terminology and International Classification of Diseases, Tenth edition (ICD-10) codes. Cohorts were stratified based on a history of prior PK or EK with >6 months follow-up. Propensity score matching was performed on both cohorts to control for age at index, sex, race, ethnicity, and the diagnosis of Fuchs dystrophy and keratoconus. The incidence of acute CME during a 6-month postoperative follow-up period was assessed. Odds ratios were calculated between cohorts. Results A total of 2516 eyes were included in the study (PK: 1258; EK: 1258). At six months postoperatively, the incidence of acute CME in the EK cohort (46 of 1258) was significantly higher than in the PK cohort (20 of 1258) (P = 0.0012) (OR 0.426, 95% confidence interval 0.25–0.72). Conclusions Our findings suggest that the incidence of acute CME is higher in patients undergoing EK compared to PK.
Robotic vs Laparoscopic Cholecystectomy: Preoperative and Intraoperative Severity-Adjusted Outcomes with Strasberg-Classified Bile Duct Injury
Kandil, Omneya, Rehman, Nisha, Saleeb, Andrew, Thompson, Emily, Krosch, Tara, Veenstra, Benjamin, Nelson, Megan, Abutaka, Ahmad, Fong, Zhi Ven, Jorge, Irving, Joshi, Devendra, Kandil, Omneya , Saleeb, Andrew G. , Krosch, Tara C., Beckermann, Jason , Nelson, Megan H., Fong, Zhi Ven , Jorge, Irving

Mayo Clinic

Journal of the American College of Surgeons | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/xcs.0000000000002118 | PMID 42566036 Get It

Background: Whether robot-assisted cholecystectomy reduces bile duct injury compared with laparoscopic cholecystectomy remains uncertain because prior studies have inadequately accounted for disease severity and have rarely classified injury severity using standardized criteria. This study compared perioperative outcomes after robot-assisted and laparoscopic cholecystectomy across a large healthcare system while adjusting for operative complexity. Study Design: Adults undergoing robot-assisted or laparoscopic cholecystectomy within the Mayo Clinic Enterprise (2014–2025) were retrospectively evaluated. Propensity score weighting adjusted for demographics, surgeon case volume, learning curve, and disease severity using the Tokyo Guidelines and Parkland grading system in patients with acute cholecystitis. The primary outcome was bile duct injury; secondary outcomes included general and procedure-specific complications. Results: Among 23,513 patients (19,998 laparoscopic; 3,515 robotic), robot-assisted cholecystectomy was used more frequently for Parkland grade ≥3 disease. Overall, 227 bile duct injuries occurred (204 laparoscopic; 23 robotic), corresponding to absolute risks of 1.02% and 0.65%, respectively (absolute risk difference −0.37%, 95% CI −0.72% to −0.02%; number needed to treat, 273). Robot-assisted cholecystectomy was associated with lower odds of conversion to open surgery, 30-day readmission, and mortality, shorter hospital stay (β −0.56, 95% CI −0.66 to −0.45; P<0.001), and a 5-minute longer median operative time. In acute cholecystitis, robot-assisted cholecystectomy was associated with lower adjusted odds of bile duct injury (aOR 0.29, 95% CI 0.07–0.78; P=0.011). Conclusions: After adjustment for disease severity and surgeon-related factors, robot-assisted cholecystectomy was associated with lower odds of bile duct injury in acute cholecystitis and improved perioperative outcomes, including shorter hospitalization and lower conversion rates, despite greater use in more complex cases.
Accelerating Evidence-Based Practices in Acute Kidney Injury
Brown, Jeremiah R. , Rabin, Borsika A. , Akcan‐Arikan, Ayse , Awdishu, Linda , Bagshaw, Sean M. , Brookman‐Frazee, Lauren , Cerdá, Jorge , Granado, Rolando Claure‐Del , Ghazi, Lama , Goldstein, Stuart L. , Liu, Kathleen D., Mottes, Theresa, Selby, Nicholas M. , Vijaykumar, Aarthi, Zarbock, Alexander, Neyra, Javier A. , Rewa, Oleksa G , Rabin, Borsika A , Akcan-Arikan, Ayse , Awdishu, Linda , Bagshaw, Sean M , Brookman-Frazee, Lauren , Cerdá, Jorge , Claure-Del Granado, Rolando , Ghazi, Lama , Goldstein, Stuart L , Jeong, Rachel , Kashani, Kianoush B , Koyner, Jay L , Macedo, Etienne , Pannu, Neesh , Reddy, Yuvaram N V , See, Emily , Selby, Nicholas M , Siew, Edward D , Silver, Samuel A , Srinsawat, Nattachai , Stadnick, Nicole A , Vijaykumar, Aarthi , Wald, Ron , Wilson, F Perry , Ronco, Claudio , Ostermann, Marlies , Mehta, Ravindra L , Neyra, Javier A , Kashani, Kianoush , Koyner, Jay L. , Liu, Kathleen D. , Macedo, Etienne , Mottes, Theresa , Pannu, Neesh , Reis, Thiago , Siew, Edward D. , Silver, Samuel A. , Wilson, F. Perry , Zarbock, Alexander , Ronco, Claudio , Ostermann, Marlies , Mehta, Ravindra L.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2215/cjn.0000001205 | PMID 42537020 Get It

Scientific evidence regarding AKI and acute kidney care has advanced in recent years. However, a knowledge gap remains on the implementation of these evidence-based practices (EBPs) into clinical care. Implementation science (IS) is focused on ensuring that this knowledge is translated in an effective, efficient and sustainable fashion. Objectives: 1) Define the current status of IS; 2) Define a roadmap for accelerating IS with a focus on patient/care partner advocacy, digital tool application, social determinants of health, and resource-limited settings; and 3) Develop a robust and broad research agenda incorporating IS methodology into the programs. Evidence Review: ADQI XXXV was conducted through a modified Delphi process with virtual meetings preceding an in-person meeting. Five workgroups were determined a priori to focus on 1) IS definitions and methods applicable to AKI and acute kidney care; 2) IS literature in AKI and acute kidney care; 3) Innovations in IS to accelerate the adoption, adherence to, and sustainment of EBPs in AKI and acute kidney care; 4) IS methods in resource-limited settings; and 5) Recommendations to identify and evaluate EBPs that are ready for implementation or de-implementation. Prior to the in-person meeting, each workgroup met virtually to review the literature and develop framework questions to address their objectives. During the two-day in person meeting, through iterative discussions, questions and supporting statements were finalized. These questions and statements were agreed upon through voting to achieve consensus, defined as agreement of ≥80%. Conclusions and Relevance: We report a structured multidisciplinary consensus for defining the role of IS in AKI and acute kidney care. Future programs should address these consensus questions and apply these statements along with IS methodology in the translation of science into clinical practice and the implementation/de-implementation of EBPs in clinical care.
Impact of Narrative-Focused Feedback Forms in a Pulmonary and Critical Care Medicine Fellowship
Olson, Emily M. , Arnold, Jason , Jain, Priya G. , Schroedl, Clara , Arnold, Jason M

Mayo Clinic

ATS Scholar | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/atsscholar/aapag038 | PMID 42535904 Get It

Abstract Background Existing formal feedback systems in graduate medical education often rely heavily on intangible Likert Scales linked to ACGME milestones as an end-of-rotation summative assessment. However, more frequent, actionable, formative feedback based on observations is essential to personal growth. Objective To evaluate the impact of changing from a milestone-based evaluation form to a brief narrative-based feedback form in a Pulmonary Disease and Critical Care Medicine (PCCM) fellowship as an exploratory pilot project. Our aim was to describe change in perception of feedback quality and the impact on Clinical Competency Committee (CCC) decisions. Methods We compared the quality of written rotation feedback before and after implementing a shorter feedback form on January 1, 2024 for 15 PCCM fellows at a single large academic institution using the Quality of Assessment for Learning (QuAL) score, (July 2023-December 2023 compared to January 2024-July 2024), fellow pre- and post-surveys (December 2023 and June 2024) and a CCC focus group (June 2024). Results Overall QuAL score improved significantly after narrative-based feedback form implementation (2.71 pre [n = 75] vs 3.70 post [n = 85], p &lt; 0.001). Surveys had 13/14 (92.8%) fellows respond pre-intervention and 8/14 (57.1%) post-intervention. There was significant improvement in the number of fellows indicating they could identify new learning goals based on written feedback after implementation of the new form (23.1% pre vs 75.0% post, p = 0.03). The CCC focus group with 5 of 8 eligible faculty participating described milestone decisions were better supported by more detailed narratives. Conclusions Implementing a brief narrative-based form improved feedback quality and the number of trainees able to create learning goals. The CCC identified that the new form provided better details to support milestone recommendations.
A Pediatric Resident Physician Coaching Program With Faculty Retreat Developed in Partnership With a Master Certified Coach
Fashina, Oluwatomini, Thorvilson, Megan J. , Mavis, Stephanie C. , Thorn, Patti M. , Pittock, Siobhán T. , Munger, Kayla, McKone, Justin , Raevsky, Emily, Johnson, Katie L. , Thorvilson, Megan , Mavis, Stephanie , Pittock, Siobhan , Munger, Kayla

Mayo Clinic

MedEdPORTAL | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11624 | PMID 42539593 Get It

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer
Isaacs, Claudine, Nanda, Rita, Yau, C, Chien, A. Jo, Hershman, Dawn L., Stringer-Reasor, Erica M., Wallace, Anne M., Clark, Amy S., Kennedy, Laura C., Sanford, Amy, Boughey, JC , Albain, Kathy S. , Pusztai, Lajos, Kalinsky, Kevin M., Beckwith, Heather, Williams, Nicole O., Han, Hyo S., Falkson, Carla, Arora, Mili, Pohlmann, Paula R., Rozenblit, Mariya, Marshall, Natalie, Chen, Yunn-Yi, McGuinness, Julia E., Howard, Frederick M., Chen, Nan, Khoury, Katia, Lancaster, Rachael, Douglas, Emily, Wei, Mei, Mainor, Candace, LeStage, Barbara, Matthews, Jeffrey B. , Perlmutter, J, Symmans, W. Fraser, Yee, Douglas, Hylton, Nola M., Veer, Laura van ‘t , Rugo, Hope S., Berry, Donald A., Esserman, Laura J., Isaacs, Claudine , Yau, Christina , Chien, A. Jo , Hershman, Dawn L. , Stringer-Reasor, Erica , Thomas, Alexandra , Vaklavas, Christos , Clark, Amy S. , Kennedy, Laura Carpin , Pusztai, Lajos , Kalinsky, Kevin M. , Beckwith, Heather , Han, Hyo S , Falkson, Carla I. , Arora, Mili, Elias, Anthony , Pohlmann, Paula R. , Rozenblit, Mariya , Trivedi, Meghna S. , McGuinness, Julia Elizabeth , Howard, F , Khoury, Katia , Yeung, Kay T. , Douglas, Emily, Mainor, Candace , LeStage, Barbara , Delson, Amy , Asare, Adam L. , Swigart, Lamorna Brown , Hirst, Gillian L. , Symmans, W. Fraser , Yee, Douglas , Veer, Laura J. van’t , Rugo, Hope S. , DeMichele, Angela , Berry, Donald A., Esserman, Laura J.

Mayo Clinic

JAMA Oncology | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.2576 | PMID 42530945 Get It

Importance Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. Objective To evaluate the combination of anti−programmed cell death 1 protein (PD-1) cemiplimab and anti−lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2 -negative early-stage, high-risk breast cancer. Design, Setting, and Participants The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2 -negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. Interventions Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. Main Outcomes and Measures Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. Results A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2 , 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2 -negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). Conclusions and Relevance In this randomized clinical trial, the combination of PD-1 and anti−LAG-3 inhibition with standard NAC was effective in early-stage ERBB2 -negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. Trial Registration ClinicalTrials.gov Identifier: NCT01042379
Rapid diagnosis of fever etiology using wearable temperature monitoring and machine learning
Khan, Shihan N., Ren, X., Wittrup, Emily, Madhukar, Rashmi, Flora, Christopher , Mayhew, Kelly, Rozwadowski, Michelle, Winnega, Eric, Leopold, Kay, Paludo, Jonas, Binder, Adam F., Ghosh, Monalisa, Frame, David, Craig, Erin, Braun, Thomas , Sung, Anthony D., Choi, Sung Won, Tewari, Muneesh , Choi, Sung Won , Choi, Sung Won , Lee, Seungwoo , Wittrup, Emily M. , Rozwadowski, Michelle , Leopold, Kay E., Weinberg, Jason B. , Paludo, Jonas , Binder, Adam Finn , Ghosh, Monalisa , Chanderraj, Rishi , Sung, Anthony D. , Najarian, Kayvan

Mayo Clinic

No container title available | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.27.26359010 | PMID 42620146 Get It

Abstract Introduction Distinct temperature patterns have long been recognized to correlate with fevers of differing etiologies. While the use of wearable sensors for high-frequency temperature monitoring (HFTM) on a near minute-by-minute basis has been shown to detect fevers earlier than standard-of-care nursing vital sign assessments in hospitalized patients, leveraging these high-resolution datasets to computationally identify unique digital signatures for real-time diagnosis of underlying fever etiology has not been widely explored. Diagnostic uncertainty is common in patients undergoing hematopoietic stem cell transplantation (HCT), with only 20–30% of febrile neutropenic episodes being microbiologically documented. We hypothesized that unique temperature patterns extracted from HFTM data collected during episodes of febrile neutropenia could be used to develop a supervised machine learning classifier capable of accurately predicting underlying fever etiology in HCT patients. Methods We analyzed 68 clinically independent fever episodes recorded in HCT patients (n=90) outfitted with an FDA-cleared wireless temperature sensor (TempTraq®, BlueSpark Technologies) that measured axillary temperature every 2 minutes throughout hospitalization. Time-series features were extracted from temperature traces spanning 1 hour before to 3 hours after fever onset and used to train a suite of machine-learning models to distinguish engraftment fevers from other fever etiologies. Model training and evaluation were performed using repeated stratified 5-fold patient-level cross-validation, yielding 100 train-test evaluations. Results Among all classification models, the logistic regression classifier provided the best overall performance and interpretability, achieving 94% specificity (95% CI, 0.84–1.0) for identifying engraftment fevers with a mean AUROC of 0.88 ± 0.10. Feature importance analysis demonstrated that both clinical variables and HFTM-derived temperature dynamics contributed to model performance, with a strong reliance on time-series features captured within the first 4 hours of fever onset. Conclusion Our study provides a demonstration that continuous temperature data collected from patients outfitted with wearable sensors can be leveraged not only for early fever detection but also for machine learning–based diagnosis of fever etiology. These findings suggest that dynamic temperature patterns contain clinically meaningful physiologic information that with further studies could support real-time diagnostic decision-making and guide safe de-escalation of empiric antibiotics during febrile neutropenia in patients undergoing intensive cancer therapy.
Impact of Cardiomyopathy and Arrhythmia Genetic Testing on Clinical Management Decisions
Morales, Ana , Ting, Yi‐Lee , Bucknor, Brianna, Chahal, C. Anwar A. , Judge, Daniel P. , Owens, Anjali , Wang, Jessica , Alkhayat, Mohamad, Barker, Naomi, Betts, Megan , Chowns, Jessica, Eberly, Rebecca M, Hoffman‐Andrews, Lily , Koduri, Ajit, Padmanabhan, Arun , Wojciak, Julianne , Higgs, Emily , Judge, Daniel P , Owens, Anjali T , Wang, Jessica , Alkhayat, Mohamad , Barker, Naomi , Betts, Megan , Esplin, Edward D , Hoffman-Andrews, Lily , Nair, Ajith P , Padmanabhan, Arun , Vedantham, Vasanth , Wojciak, Julianne , McNally, Elizabeth M , Chahal, Choudhary Anwar A , Morales, Ana , Bucknor, Brianna A., Chowns, Jessica L., Eberly, Rebecca, Higgs, Emily , Huth, Emily A. , Koduri, Ajit , Nair, Ajith, Esplin, Edward D. , McNally, Elizabeth M.

Mayo Clinic

No container title available | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.22.26358740 | PMID 42619823 Get It

ABSTRACT Background Genetic testing for cardiomyopathy and arrhythmia (CM/ARRH) provides diagnostic information and informs screening for at-risk relatives. Clinical guidelines recommend genetic testing for these conditions; however, data on how genetic test results influence clinical management recommendations are limited. Here, we determined the frequency of cardiologist-recommended management changes for patients following CM/ARRH genetic testing. Methods This was a retrospective cross-sectional study of patients referred for multigene panel testing between April 2016 and April 2024. Genetically-experienced cardiologists at multicenter academic clinical practices were recruited for participation to complete surveys indicating clinical decision making on patients who had genetic testing. Cases for review were randomly selected to have both positive and non-positive results. Results Among 249 patients (138 positive, 111 non-positive), 136 (54.6%) received clinical management recommendations for their own or their at-risk relatives’ care. Of these, 75 (55.1%) received recommendations for the patient’s own care, most frequently additional diagnostic tests/procedures (n=33). Compared to non-positive results, patients with positive results were more likely to receive recommendations for their own management (66/138, 47.8% vs 9/111, 8.1%; P<0.00001). Patients with positive results in arrhythmogenic cardiomyopathy genes had 263% higher odds of recommended management changes compared to those with TTN (OR=3.63, CI:1.40-9.84, P=0.009). Conclusions The results from CM/ARRH genetic testing on affected patients influenced cardiologists’ medical decision making and management recommendations. Additional research is needed to evaluate how genetic testing for CM/ARRH impact health outcomes.
Characteristics of Gender-Diverse Patients With Breast Cancer
Cortina, Chandler S., Brazauskas, Ruta , Flanagan, Meghan R., Dill, Ellen D., Joseph, Kathe-Ann P., Trifonov, Alexandr , Kim, Esther A. , Kantor, Olga, Barmettler, Gabi , Rosenberger, Laura H., Jordan, Sumanas W., Perez, Megan M. , Jimenez, Rachel B., Smart, Alicia , Walker, J C, Lautner, Meeghan A., Siegel, Emily L., Brabender, Danielle , Al-Hilli, Zahraa, Cassidy, Michael R., Weiss, Anna, McCaffrey, Rachel L., Lee, M Catherine, Kaoutzanis, Christodoulos, Nguyen, Khoa N., Son, Jennifer D., Williams, Austin D., Madrigrano, Andrea, McLaughlin, Sarah A., Stolley, Melinda, Cortina, Chandler S. , Flanagan, Meghan R. , Mukhtar, Rita A. , Kantor, Olga , Rezak, Kristen M. , Rosenberger, Laura H. , Jimenez, Rachel , Kopkash, Katherine A. , Hughes, Tasha M. , Walker, Jasmine C. , Lautner, Meeghan Ann, Siegel, Emily , Al‐Hilli, Zahraa , Cassidy, Michael Ryan , Weiss, Anna, McCaffrey, Rachel Louise , Kaoutzanis, Christodoulos , Son, Jennifer D. , Williams, Austin David , Petroll, Andrew E. , Stolley, Melinda R.

Mayo Clinic

JAMA Network Open | July 23, 2026 | Volume: 9 | Issue: 7 | Pages: e2624824

10.1001/jamanetworkopen.2026.24824 | PMID 42490110 Get It

Importance Limited granular data exist on breast cancer in transgender, nonbinary, and/or gender-diverse (TGD) individuals. Objective To describe patient demographic and tumor clinicopathological variables, clinically relevant risk factors, method of breast cancer detection, treatment characteristics, and locoregional outcomes and to estimate a 5-year breast cancer–specific survival (BCSS). Design, Setting, and Participants This cohort study obtained data on patients treated from 1990 to 2023 from 22 US academic medical centers using institutional databases, electronic medical records, and tumor registries. Included participants were TGD individuals 18 years or older with stage 0 to IV breast cancer. A comparative breast cancer cohort was selected from the 2016 to 2021 Surveillance, Epidemiology, and End Results Program (SEER) breast cancer dataset. Data were analyzed from January to October 2025. Exposure Breast cancer. Main Outcomes and Measures Estimated 5-year BCSS and locoregional recurrence rates. Wilcoxon rank sum and χ 2 tests were used to compare continuous and categorical variables. Kaplan-Meier analysis was used to estimate 5-year BCSS. Results A total of 112 TGD persons (median [IQR] age at diagnosis, 42.5 [36.5-51.0] years; 104 individuals [92.9%] were assigned female at birth) with breast cancer and 1 with bilateral disease were included in the analysis. Forty-three patients (38.4%) used gender-affirming hormone therapy before diagnosis. Among the entire cohort, 58 patients (51.8%) detected their own breast cancer, 68 (60.7%) had a familial breast cancer history, and 16 (14.3%) had a pathogenic germline variant. Tumors were predominantly hormone receptor positive (96 [85.7%]) and early stage (29 [25.7%] ductal carcinoma in situ [DCIS]; 51 [45.1%] stage I). The TGD cohort, compared with patients with breast cancer in the SEER dataset (N = 480 915), was younger (median [IQR] age, 42.5 [36.5-51.0] years vs 62.0 [52.0-72.0] years), had a higher proportion of persons assigned male at birth (8 [7.1%] vs 3522 [0.7%]), more often had progesterone receptor–positive disease (89 [79.5%] vs 335 491 [69.8%]), and presented with earlier-stage disease (eg, DCIS: 29 [25.9%] vs 79 604 [16.6%]). With a median (IQR) follow-up time for the TGD cohort of 38 (24-74) months, 5-year BCSS was favorable at 96.2% (95% CI, 85.3%-99.0%). Conclusions and Relevance This cohort study of TGD patients with breast cancer found that this population was young and often detected their own tumors via self-examination, suggesting opportunities to improve early detection through screening for individuals at elevated risk. Although short-term BCSS appeared favorable, prospective research is essential to define evidence-based guidelines and elucidate long-term outcomes.